FDA enforcement record (Ongoing): Presence of foreign tablets/capsules. [source]
From General Health Education to Occupational Risk Awareness
Historically, this domain has served as a general health and science information resource, providing broad educational content on a range of medical topics. This foundation established a baseline of public awareness regarding medication side effects and patient safety. Within this general context, one area that has received increasing attention is the long-term neurological impact of certain prescription drugs. Specifically, the transition from general health literacy to a more focused occupational concern begins with recognizing that exposure to specific pharmaceutical agents can create distinct risk profiles. In the mass production setting, workers may handle or be exposed to compounds such as metoclopramide, the active ingredient in Reglan, during manufacturing, packaging, or quality control processes. This occupational exposure shifts the discussion from a purely clinical or informational framework to one involving workplace safety protocols and potential liability. The bridge concept here is straightforward: what was once a matter of general patient education now becomes a targeted concern for industrial hygiene and employee health monitoring. The legacy of general health information thus provides the necessary background for understanding why certain exposures in a production environment warrant careful documentation and risk assessment, without delving into specific disease mechanisms or making causal claims.
Mechanism and Epidemiology of Reglan-Induced Tardive Dyskinesia
The mechanistic pathway linking Reglan to TD involves dopamine receptor blockade in the basal ganglia, leading to supersensitivity of dopamine receptors and subsequent involuntary movements. This is consistent with the pharmacology of metoclopramide as a dopamine antagonist. The risk of TD from metoclopramide is estimated to be low, with a recent real-world epidemiology study (2011-2020) reporting incidence rates of approximately 0.1% per 1000 patient-years, far below earlier estimates of 1%-10% (https://pubmed.ncbi.nlm.nih.gov/31050085/). High-risk groups include elderly females, diabetics, patients with liver or kidney failure, and those on concomitant antipsychotic therapy, which reduces the threshold for neurological complications (https://pubmed.ncbi.nlm.nih.gov/31050085/). Another study using the MarketScan database analyzed TD incidence in adults from 2011 to 2020, comparing rates among metoclopramide-treated gastroparesis patients, untreated patients, and the general population, with Poisson regression adjusting for person-years at risk (https://pubmed.ncbi.nlm.nih.gov/41588797/).
Claim Valuation Factors for Reglan Tardive Dyskinesia Settlements
Settlement considerations for affected patients hinge on several factors. The adequacy of warnings regarding Reglan and TD is a key risk anchor. The FDA boxed warning clearly states that metoclopramide can cause TD, that risk increases with duration and cumulative dose, and that Reglan is contraindicated in patients with a history of TD (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). However, historical prescribing practices may have deviated from these guidelines, leading to prolonged use beyond 12 weeks. The timeline between exposure and documented harm is critical: TD can develop after months or years of use, and symptoms may persist or become permanent even after drug discontinuation. Claim valuation factors include the severity and irreversibility of TD, the duration of Reglan use, the presence of risk factors (e.g., age, diabetes, renal impairment), and the extent to which warnings were communicated to patients. Patients who developed TD after prolonged use without adequate monitoring or warning may have stronger claims. Conversely, cases where treatment was short-term and warnings were provided may have lower valuation. In summary, Reglan-induced TD is a serious, potentially irreversible condition with a low but real incidence. Risk factors include prolonged use, high cumulative doses, and patient demographics such as elderly females and diabetics. Settlement valuation depends on the adequacy of warnings, duration of exposure, and individual patient circumstances. Clinicians should adhere to prescribing guidelines, limit treatment to 12 weeks, and monitor for TD symptoms.
Important Notice
This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.
Frequently Asked Questions
What is the link between Reglan and tardive dyskinesia?
Reglan (metoclopramide) is a dopamine antagonist that can cause tardive dyskinesia (TD), a potentially irreversible movement disorder. The risk increases with longer treatment duration and higher cumulative doses. The FDA boxed warning states that metoclopramide can cause TD, and the drug should be used for the shortest duration necessary (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397).
What factors affect the value of a Reglan TD settlement claim?
Key factors include the severity and irreversibility of TD, duration of Reglan use, presence of risk factors (e.g., age, diabetes, renal impairment), and the adequacy of warnings provided to the patient. Cases involving prolonged use beyond 12 weeks without proper monitoring may have higher valuation (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397).
Does submitting information create an attorney-client relationship?
No. Submission requests an initial records screening only and does not create an attorney-client relationship.
This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.
Community Resource & Benefit Desk
Request archival records or inquire about member-exclusive transition and benefit programs.